Drug intelligence / Profile preview

OTX-M

Development stage: Unknown
Modality: Small Molecules

Overview

OTX-M is a macrodiolide analog of Aplysiatoxin (ATX), a bioactive polyketide natural product. It is synthesized from anhydroATX, a dehydrated form of ATX. The synthesis of OTX-M, among other ATX analogs, resulted in revisions to its ring structure.

Other names: OTX-M

Beyond the preview

Go deeper on OTX-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTX-M.

Explore the full profile